Emmaus Life SciencesEMMA -16.67% Gross Margin % is 91.52% as of Mar. 2026, which is 0% below its 10-year median of 91.55. The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, Emmaus Life Sciences ranks better than 90.38% on this metric.
The historical rank and industry rank for Emmaus Life Sciences's Gross Margin % or its related term are showing as below:
EMMA'
s Gross Margin % Range Over the Past 10 Years
Min: 37.08 Med: 91.55 Max: 95.47
Current: 93.35
During the past 13 years, the highestGross Margin % of Emmaus Life Sciences was 95.47%. The lowest was 37.08%. And the median was 91.55%.
EMMA's Gross Margin % is ranked better than 90.38% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs EMMA: 93.35
Emmaus Life Sciences had a gross margin of 91.52% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Emmaus Life Sciences was 1.60% per year.
Emmaus Life Sciences (OTCPK:EMMA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Emmaus Life Sciences had a gross margin of 91.52% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Emmaus Life Sciences Gross Margin % Related Terms
Emmaus Life Sciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs CERO, AGTX, WINT: Gross Margin % Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Emmaus Life Sciences (EMMA) has a Gross Margin % of 91.52% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Emmaus Life Sciences and its competitors. This is near median its historical median of 91.55. Over the past decade, Emmaus Life Sciences' Gross Margin % has ranged from 37.08 to 95.47. According to the industry distribution chart, Emmaus Life Sciences ranks #71 out of 738 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Emmaus Life Sciences' Gross Margin % too high?
Emmaus Life Sciences' current Gross Margin % of 91.52% is near median its 10-year median of 91.55. Over the past 10 years, this metric has ranged from a low of 37.08 to a high of 95.47. The Biotechnology industry median Gross Margin % is 60.94. Emmaus Life Sciences' value of 91.52% is 50.2% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #71 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' Gross Margin % compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #71 out of 738 companies for Gross Margin %. This places Emmaus Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. Emmaus Life Sciences' value of 91.52% is 50.2% above this benchmark. Historically, Emmaus Life Sciences' own Gross Margin % has ranged from 37.08 to 95.47 over the past decade. While the company's 10-year median is 91.55 vs. the industry median of 60.94, Emmaus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Gross Margin % of 91.52% is 50.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Gross Margin % is 91.52%, which is near median its own 10-year median of 91.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Gross Margin % is 91.52%, which is near median its 10-year median of 91.55 and 50.2% above the Biotechnology industry median of 60.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Gross Margin % is 91.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 